Bausch + Lomb and Novaliq secured approval for their dry eye disease drop on Thursday, to be marketed as Miebo.
The drug, also known as perfluorohexyloctane ophthalmic solution or formerly NOV03, targets tear evaporation, a leading cause of dry eye disease. Bausch + Lomb CEO Brent Saunders expects the drug to be available in the second half of this year.
“Today’s FDA decision marks a huge milestone for Bausch + Lomb as MIEBO becomes our first prescription pharmaceutical eye treatment approved by the FDA since we became an independent, publicly traded eye health company,” said Andrew Stewart, president of ophthalmic pharmaceuticals, in a news release.
Continue reading Endpoints with a free subscription
Unlock this story immediately and join over 1[ads1]69,100 biopharma professionals who read Endpoints daily – and it’s free.